ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Lupus"

  • Abstract Number: 0528 • ACR Convergence 2021

    Interferon Pathway Lupus Risk Alleles Modulate Risk of Death from Acute COVID-19

    Ilona Nln1, Ruth Fernandez Ruiz2, Theresa Wampler Muskardin3, Stephanie Tuminello2, Mukundan Attur2, Eduardo Itturate2, Christopher Petrilli2, Steven B. Abramson4, Aravinda Chakravarti2 and Timothy Niewold1, 1Colton Center for Autoimmunity NYU School of Medicine, New York, NY, 2NYU Grossman School of Medicine, New York, NY, 3Colton Center for Autoimmunity, NYU School of Medicine, New York, NY, 4New York University School of Medicine, New York, NY

    Background/Purpose: Type I interferon (IFN) is critical in our defense against viral infections. Increased type I IFN pathway activation is a genetic risk factor for…
  • Abstract Number: 0625 • ACR Convergence 2021

    Brief Tailored Clinic Intervention (A-MATIC) Targets Nonadherence During SLE Visits: Two-year Sustainability and Outcomes

    Shivani Garg1, Betty Chewning1, Shelby Gomez1 and Christie Bartels2, 1UW Madison, Madison, WI, 2University of Wisconsin School of Medicine and Public Health, Madison, WI

    Background/Purpose: Up to 83% of SLE patients are nonadherent to hydroxychloroquine (HCQ) which can result in up to 8-fold higher risk of early death. Yet,…
  • Abstract Number: 0783 • ACR Convergence 2021

    Transmission Disequilibrium Testing Meets Next Generation Sequencing: Applying TDT to Whole Genome Data in Childhood-Onset Systemic Lupus Erythematosus

    Kathleen Vazzana1, Anthony Musolf2, Joan Bailey-Wilson3, Zuoming Deng3, Mariana Kaplan3 and Laura Lewandowski2, 1National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH)/Children's National Hospital, Washington, DC, 2NIAMS, NIH, Rockville, MD, 3National Institutes of Health, Bethesda, MD

    Background/Purpose: Systemic lupus erythematosus (SLE) is a systemic autoimmune disorder that is more severe in children than adults. Due to aggressive disease in childhood-onset SLE…
  • Abstract Number: 0891 • ACR Convergence 2021

    Quality of Life Assessment in an Indian Inception Cohort (INSPIRE) of SLE Using Lupus QoL Questionnaire

    Liza Rajasekhar1, Dhundra Bhavani1, Sneha Tota2, Vishnupriya Vijayalekshmi3, Ranjan Gupta4, Chengappa Kavadichanda5, Vineeta Shobha6, VirSingh Negi7 and Amita Aggarwal2, 1NIMS, Hyderabad, India, 2Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, 3AIIMS, New delhi, delhi, India, 4AIIMS, New delhi, Ne Delhi, India, 5JIPMER, Pondicherry, India, 6Saint Johns Medical college, Bengaluru, Bengaluru, India, 7Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India

    Background/Purpose: Lupus quality of life (Lupus QoL) questionnaire is a disease specific patient reported outcome that is available in multiple languages1. Indian SLE inception cohort…
  • Abstract Number: 1765 • ACR Convergence 2021

    Should SLE Patients Entering Clinical Trials Be Required to Have at Least One BILAG A and/or Two BILAG B Domain Scores?

    Ewa Olech1, Faizi Hussain2 and Joan Merrill3, 1IQVIA, Las Vegas, NV, 2IQVIA, Redding, United Kingdom, 3Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: High placebo response rates have challenged interpretation of clinical trial results in SLE and may have contributed to failure of some effective treatments. One…
  • Abstract Number: 006 • 2020 Pediatric Rheumatology Symposium

    Increasing Rates of Standardized Depression Screening in Youth with Systemic Lupus Erythematosus in a Pediatric Rheumatology Clinic

    Victoria Newsome 1, Jodi Dingle 2, Manda Mitchell 3, Thomas Brent Graham 4 and Alaina Davis5, 1Nashville, 2Vanderbilt University Medical Center, Nashville, Tennessee, 3Nashville, Tennessee, 4Vanderbilt University Medical Center, Nashville, 5Monroe Carell Jr. Children’s Hospital at Vanderbilt, Nashville, Tennessee

    Background/Purpose: Depression is common among youth with SLE.  Early identification and treatment of depression has the potential to improve health outcomes for youth with SLE.…
  • Abstract Number: 031 • 2020 Pediatric Rheumatology Symposium

    Exome Sequencing for Early Pediatric Systemic Lupus Erythematosus: Standard of Care in 2020?

    Yike Jiang1, Bo Yuan 1, Marietta DeGuzman 1, M. Cecilia Poli 2, Justin Branch 1, Andrea Ramirez 3, Martha Curry 1, Maria Pereira 4, Amanda Brown 1, W. Blaine Lapin 5, Sarah Nicholas 1, Lisa Forbes 1, Nicholas Rider 1, Levi Watkin 1, Jennifer Rammel 6, Ankur Kamdar 7, Melissa Mizesko 8, Juan Carlos Becerra 9, Emilina Lim 10, Eyal Muscal 11, Anaid Reyes 1, Zeynep Coban-Akdemir 1, James Lupski 1, Ivan Chinn 1 and Tiphanie Vogel 1, 1Baylor College of Medicine, Houston, 2Universidad del Desarrollo, Santiago, Chile, 3Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, 4Assistant Professor, Section of Rheumatology, Division of Pediatrics, Baylor College of Medicine, Houston, Texas, 5, 6Section of Nephrology and Rheumatology, Department of Pediatrics, University of Florida Health Jacksonville, Jacksonville, Florida, 7Houston, 8Driscoll Children's Hospital, Corpus Christi, 9Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru, 10Children's Hospital Orange County, Orange County, 11Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, houston

    Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with multifactorial etiology. Identification of monogenic causes of pediatric SLE (pSLE) has yielded important insights…
  • Abstract Number: 071 • 2020 Pediatric Rheumatology Symposium

    Patient Reported Outcomes and Resilience in Pediatric Systemic Lupus Erythematosus

    Lauren Ambler1, Rula Issa 2, Stephanie Pan 2 and Rebecca Trachtman 2, 1Mount Sinai Hospital, New York, 2Icahn School of Medicine at Mount Sinai, New York

    Background/Purpose: It has been established that pediatric Systemic Lupus Erythematous (pSLE) is associated with lower health-related quality of life (HRQOL); however, there are few studies…
  • Abstract Number: 088 • 2020 Pediatric Rheumatology Symposium

    Sun Protection Use in Patients Followed in a Pediatric Rheumatology Clinic in an Urban Setting

    Tamara Tanner1, Gabriel Tarshish 2, Dawn Wahezi 3 and Tamar Rubinstein 4, 1Montefiore Medical Center, Bronx, 2Children's Hospital at Montefiore, New York, 3Children's Hospital at Montefiore, Bronx, 4Albert Einstein College of Medicine, White Plains

    Background/Purpose: Exposure to sunlight has been implicated as a major contributing factor in the pathogenesis of systemic lupus erythematosus (SLE) and juvenile dermatomyositis (JDM). Despite…
  • Abstract Number: 168 • 2020 Pediatric Rheumatology Symposium

    Examining the Role of IFN-I and Langerhans Cell ADAM17 in Lupus Photosensitivity

    Keila Veiga1, Noa Schwartz 2, William Shipman 1, Marvin Sandoval 3, Thomas Li 1, Yurii Chinenov 1, David Oliver 1, Ali Jabbari 4, James Krueger 5, Sarah Taber 1, Niroshana Anandasabapathy 6 and Theresa Lu 1, 1Hospital for Special Surgery, New York, 2Albert Einstein College of Medicine/Montefiore Medical Center, New York, 3Weill Cornell Graduate School of Medical Sciences, New York, 4University of Iowa, Iowa City, 5Rockefeller Center, New York, 6Weill Cornell Medicine, New York

    Background/Purpose: Photosensitivity resulting in inflammatory skin lesions is a hallmark of cutaneous lupus.  Lesions can be disfiguring and have a negative impact on quality of…
  • Abstract Number: 689 • 2019 ACR/ARP Annual Meeting

    Patterns of High Disease Activity Status and Outcomes in Systemic Lupus Erythematosus

    Alberta Hoi 1, Hieu Nim 2, Rachel Koelmeyer 2, Ying Sun 3, Amy Kao 4, Oliver Guenther 3 and Eric Morand2, 1School of Clinical Sciences, Monash University, Meloburne, Victoria, Australia, 2Monash University, Melbourne, Victoria, Australia, 3Merck Healthcare KGaA, Darmstadt, Germany, 4EMD Serono Research & Development Institute, Inc., Billerica, MA

    Background/Purpose: High Disease Activity Status (HDAS), defined as ever attainment of SLEDAI-2k of 10 or greater, may be a useful indicator of overall disease severity in…
  • Abstract Number: 1199 • 2019 ACR/ARP Annual Meeting

    Improving Rates of Cervical Cancer Screening and HPV Vaccination in Patients with Lupus

    Nancy Desai1, Hanni Menn-Josephy 1, Ramon Bonegio 1, Christina Lam 1, Anna Kancharla 1 and Michael York 1, 1Boston Medical Center, Boston

    Background/Purpose: Patients with lupus have higher rates of cervical dysplasia and pre-malignant cervical lesions. At our institution, an urban referral center for patients with lupus, rates…
  • Abstract Number: 1734 • 2019 ACR/ARP Annual Meeting

    Low Bone Mineral Density Was Associated with Lupus Nephritis Irrespective of Duration on Steroid Treatment in a Large Observational Study of Juvenile Systemic Lupus Erythematosus Patients

    Anastasia-vasiliki Madenidou1, Yasmin Mahfouz 2, Oliver Cheng 2, Farah El-Sharnouby 2, Charlene Foley 2 and Coziana Ciurtin 3, 1Centre for Adolescent Rheumatology, University College London London, UK, LOndon, 2Centre for Adolescent Rheumatology, University College London London, UK, London, United Kingdom, 3Centre for Adolescent Rheumatology, University College London London, UK, Londond, United Kingdom

    Background/Purpose: An estimated 10-20% of all patients with systemic lupus erythematosus (SLE) develop clinical disease before the age of 18 years and are therefore classified…
  • Abstract Number: 2584 • 2019 ACR/ARP Annual Meeting

    Management of Cutaneous Manifestations of Lupus Erythematosus: A Systematic Review

    Jessica Fairley1, Shereen Oon 2, Amanda Saracino 3 and Mandana Nikpour 2, 1Monash University, Melbourne, Australia, 2St Vincent's Hospital, Melbourne; The University of Melbourne, Melbourne, Australia, 3University College London, London, United Kingdom

    Background/Purpose: Cutaneous lupus erythematosus (CLE), occurring with or without systemic lupus erythematosus (SLE), is a group of inflammatory skin diseases that can be very debilitating,…
  • Abstract Number: 691 • 2019 ACR/ARP Annual Meeting

    Adjusted GAPSS in Systemic Lupus Erythematosus Patients in Argentina

    Lucila Garcia1, Maria Victoria Martire 1, Sofia Velloso 1, Florencia Savy 1, Fernando Arizpe 2, Nadia Garcia 1, Adriana Testi 1, Claudia Pena 1, Dafne Capelusnik 3, Carolina Ayelen Isnardi 4, Victoria Collado 5, MARIA FLORENCIA Rodriguez 6, Cecilia Pisoni 7, Susana Mazza 8, Yessika Soria Curi 8, Adriana Seewald 9, María de la Torre 7 and Mercedes Garcia 10, 1Hospital San Martin, La Plata, Argentina, 2Hospital San Martin, Buenos Aires, Argentina, 3Instituto de Rehabilitacion Psicofisica, CABA, Ciudad Autonoma de Buenos Aires, Argentina, 4Instituto de Rehabilitación Psicofísica, Ciudad de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, 5Private clinic, buenos aires, Argentina, 6hospital rivadavia, buenos aires, Argentina, 7Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno (CEMIC), Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, 8Hospital Ángel C. Padilla, San Miguel de Tucumán, Tucuman, Argentina, 9Hospital Escuela de Agudos Dr. Ramón Madariaga, Posadas, Argentina, 10Hospital San Martín, La Plata, Argentina

    Background/Purpose: Assessment of risk both for pregnancy morbidity and thrombosis in the presence of anti-phospholipid antibodies (aPL) is still a challenge. The Global Antiphospholipid Syndrome…
  • 1
  • 2
  • 3
  • …
  • 31
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology